Sionna Therapeutics, Inc. (NASDAQ:SION) Receives $53.22 Average PT from Brokerages

Shares of Sionna Therapeutics, Inc. (NASDAQ:SION) have received a consensus recommendation of “Moderate Buy” from the thirteen analysts that are currently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation, seven have issued a buy recommendation and three have assigned a strong buy recommendation to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $53.2222.

Several research firms recently weighed in on SION. BTIG Research reaffirmed a “buy” rating and issued a $58.00 price objective on shares of Sionna Therapeutics in a report on Wednesday, May 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Sionna Therapeutics in a research note on Friday, May 8th. Stifel Nicolaus boosted their price target on shares of Sionna Therapeutics from $44.00 to $55.00 and gave the stock a “buy” rating in a research report on Monday, May 18th. Wedbush assumed coverage on shares of Sionna Therapeutics in a research note on Tuesday, May 5th. They issued an “outperform” rating and a $53.00 price target for the company. Finally, Citizens Jmp reiterated a “market outperform” rating and issued a $63.00 price objective on shares of Sionna Therapeutics in a report on Tuesday, May 26th.

Insider Buying and Selling

In other Sionna Therapeutics news, Director Peter A. Thompson sold 85,918 shares of the stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $44.86, for a total transaction of $3,854,281.48. Following the completion of the transaction, the director directly owned 2,469,959 shares of the company’s stock, valued at approximately $110,802,360.74. This trade represents a 3.36% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Orbimed Advisors Llc sold 85,918 shares of Sionna Therapeutics stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $44.86, for a total value of $3,854,281.48. Following the transaction, the director owned 2,469,959 shares in the company, valued at approximately $110,802,360.74. This trade represents a 3.36% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 989,630 shares of company stock valued at $44,987,483 over the last 90 days. 5.10% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of SION. UBS Group AG lifted its holdings in Sionna Therapeutics by 91.1% in the 4th quarter. UBS Group AG now owns 89,177 shares of the company’s stock valued at $3,669,000 after acquiring an additional 42,511 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Sionna Therapeutics by 3.7% in the 4th quarter. Vanguard Group Inc. now owns 1,184,951 shares of the company’s stock worth $48,749,000 after purchasing an additional 41,797 shares during the last quarter. Candriam S.C.A. acquired a new position in shares of Sionna Therapeutics in the 1st quarter worth approximately $9,494,000. Jennison Associates LLC raised its holdings in shares of Sionna Therapeutics by 11.8% in the 4th quarter. Jennison Associates LLC now owns 1,115,278 shares of the company’s stock worth $45,883,000 after purchasing an additional 117,903 shares in the last quarter. Finally, Eventide Asset Management LLC bought a new stake in shares of Sionna Therapeutics in the 4th quarter worth approximately $26,290,000.

Sionna Therapeutics Price Performance

Shares of Sionna Therapeutics stock opened at $45.38 on Friday. Sionna Therapeutics has a 1-year low of $16.38 and a 1-year high of $51.56. The business’s fifty day moving average price is $41.16 and its two-hundred day moving average price is $39.84. The company has a market capitalization of $2.05 billion, a P/E ratio of -23.51 and a beta of 1.33.

Sionna Therapeutics (NASDAQ:SION) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.52) by ($0.08). On average, research analysts expect that Sionna Therapeutics will post -2.57 earnings per share for the current fiscal year.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.